Paradiem’s Edwards Lifesciences EW Stock Holding History

Paradiem’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-26,783	Closed	-$2.27M	–	104
2020 Q4	$2.27M	Buy	+26,783	New	+$2.22M	0.96%	51

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Paradiem's EW Position: Q1 2021 in Review

Paradiem sold out of Edwards Lifesciences (EW) in Q1 2021, closing a stake of 26,783 shares — an estimated $2.27M sold.

Paradiem first reported a position in EW in Q4 2020 and held it in 1 quarter. The position peaked at $2.27M in Q4 2020. 1,144 funds tracked by Wall St. Rank hold EW as of Q1 2021.

Paradiem reported no remaining Edwards Lifesciences position as of Q1 2021 after selling out during the quarter.
Paradiem sold 26,783 Edwards Lifesciences shares in Q1 2021, an estimated $2.27M.
Paradiem first reported a position in Edwards Lifesciences in Q4 2020 and held it in 1 quarter.
Paradiem's Edwards Lifesciences position peaked at $2.27M in Q4 2020.
1,144 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2021.

Based on Paradiem's 13F filing for Q1 2021, filed 18 May 2021.